8-K: Synergy CHC Amends Loan, Issues Warrants to Lender

Synergy CHC Corp. has amended its term loan credit agreement, adjusting payment schedules and covenants, and issued a common stock purchase warrant to a lender.

Summary

• Synergy CHC Corp. (the "Company") entered into a Second Amendment to its Term Loan Credit Agreement with ACP Agency, LLC and its lenders, dated March 24, 2026.
• The amendment modifies the term loan's amortization schedule, interest payment mechanics, pricing, application of equity issuance proceeds, and certain covenants.
• Scheduled principal payments are now $175,000 on July 1, 2026, $175,000 on October 1, 2026, $525,000 on January 1, 2027, and $350,000 quarterly thereafter starting April 1, 2027.
• An Applicable Margin step-up of 2.00% per annum will occur if the Company fails to raise at least $10,000,000 in Net Cash Proceeds from Equity Issuances by September 30, 2026.
• The interest payment due March 2, 2026, was paid in kind (PIK) by capitalizing it to the principal. The Company can elect to pay all or a portion of the April 1, 2026 interest payment in kind.
• New financial covenants include a Minimum Consolidated Adjusted EBITDA of $500,000 for the fiscal quarter ended June 30, 2026, and $1,000,000 for the fiscal quarter ended September 30, 2026.
• The maximum Consolidated Senior Net Leverage Ratio was revised to 20.00:1.00 for the fiscal quarter ended December 31, 2025, with a revised step-down schedule thereafter.
• The Company issued a Common Stock Purchase Warrant to Acme Credit Partners Fund I, LP (the "Holder") for 3,000,000 shares of common stock at an exercise price of $0.00001 per share.
• The warrant has a ten-year term and becomes exercisable upon a "Qualified Event of Default" under the Credit Agreement.
• An issuance limitation prevents the Holder from beneficially owning more than 19.9% of outstanding common stock until stockholder approval is obtained.
• The Company will seek stockholder approval for issuances exceeding the 19.9% beneficial ownership limit at its next annual meeting, no later than June 30, 2026.
• The warrant includes a cashless (net) exercise feature after a Qualified Event of Default.
• Jack Ross, Chairman and CEO, irrevocably covenanted to vote all his beneficially owned shares in favor of the Stockholder Warrant Approval.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a distressed financing event. While the amendment provides short-term liquidity relief through PIK interest and adjusted covenants, the issuance of warrants, the high leverage ratios, and the mandatory equity raise with a penalty for non-compliance indicate significant financial challenges and potential future dilution for shareholders.

Positives

• The amendment provides flexibility for interest payments, allowing for payment-in-kind (PIK) for March 2, 2026, and optionally for April 1, 2026, which conserves cash.
• The revised amortization schedule might offer some near-term relief compared to previous terms, providing more manageable principal payments.
• The issuance of the warrant enhances collateral security for the lender, potentially strengthening the relationship with a key financing partner.
• The increase in the Change of Control definition from 30% to 40% beneficial ownership by any person or group (other than Jack Ross) provides more flexibility for ownership changes without triggering a default.

Negatives

• The issuance of 3,000,000 shares via warrant, even at a nominal exercise price, represents potential future dilution for existing shareholders.
• The warrant becomes exercisable upon a "Qualified Event of Default," indicating increased leverage for the lender in distress scenarios.
• Failure to raise $10,000,000 in equity by September 30, 2026, will result in a 2.00% per annum increase in the Applicable Margin, increasing borrowing costs.
• New minimum Consolidated Adjusted EBITDA covenants ($500,000 for Q2 2026, $1,000,000 for Q3 2026) and revised leverage ratios impose stricter financial performance requirements.
• The automatic conversion of Term SOFR Rate Loans to Reference Rate Loans effective February 1, 2026, and the limitation on electing Term SOFR until $4,000,000 in principal reduction payments are made, could lead to higher interest costs if Term SOFR is lower than the Reference Rate.
• The mandatory prepayment requirements from equity issuances (next $4,000,000 after the first $6,000,000) reduce the Company's flexibility in using capital raise proceeds.
• The increase in the maximum Consolidated Senior Net Leverage Ratio to 20.00:1.00 for Q4 2025, while seemingly high, could indicate significant existing leverage or a need for substantial headroom, which is generally a negative indicator of financial health.

Risks

• Dilution Risk: The issuance of 3,000,000 shares upon warrant exercise could dilute existing shareholders' ownership.
• Increased Borrowing Costs: Failure to meet the $10,000,000 equity raise condition by September 30, 2026, will increase the Applicable Margin by 2.00% per annum.
• Financial Covenant Breach: Failure to meet the new Minimum Consolidated Adjusted EBITDA covenants ($500,000 for Q2 2026, $1,000,000 for Q3 2026) or the revised Consolidated Senior Net Leverage Ratio could trigger an Event of Default.
• Event of Default: The warrant becomes exercisable upon a "Qualified Event of Default," which could lead to the lender exercising their right to acquire shares at a nominal price, further impacting the company during a period of financial distress.
• Shareholder Approval Risk: The Company needs to obtain stockholder approval for warrant issuances exceeding 19.9% beneficial ownership by June 30, 2026. Failure to do so could limit the lender's ability to fully exercise the warrant, potentially straining the relationship or leading to further negotiations.
• Liquidity Risk: The requirement to maintain Liquidity of at least $2,000,000 for Sanders Notes interest payments and $4,000,000 for Sanders Notes principal payments indicates ongoing liquidity management challenges.
• Refinancing Risk: The need for a Second Amendment to the credit agreement suggests ongoing financial challenges and potential difficulties in meeting original loan terms.

Future Outlook

The Company covenants to seek stockholder approval for warrant issuances exceeding the 19.9% beneficial ownership limitation at its next annual meeting, no later than June 30, 2026. The Company must raise at least $10,000,000 in Net Cash Proceeds from Equity Issuances by September 30, 2026, to avoid an increase in the Applicable Margin. Additionally, the Company must make $4,000,000 in principal reduction payments to regain the ability to elect Term SOFR-based interest. The Company is subject to ongoing financial covenants, including minimum Consolidated Adjusted EBITDA and maximum Consolidated Senior Net Leverage Ratios, with specific targets for future fiscal quarters.

Management Comments

• Jack Ross, Chairman and Chief Executive Officer, irrevocably covenanted to vote all his beneficially owned shares of common stock in favor of the Stockholder Warrant Approval referenced in the Warrant.

Industry Context

StockSavvy.ai notes that the amendment of a term loan credit agreement and the issuance of warrants to a lender often signal a company facing liquidity or operational challenges, requiring more flexible financing terms or additional security for lenders. The imposition of stricter financial covenants and the requirement for a significant equity raise by a near-term deadline suggest the company is under pressure to improve its financial position and reduce leverage. The PIK interest option is a common feature in distressed debt situations, allowing companies to conserve cash in the short term at the expense of increasing the principal amount of the debt.

Comparison to Industry Standards

• The revised maximum Consolidated Senior Net Leverage Ratio of 20.00:1.00 for Q4 2025, stepping down to 2.50:1.00 by Q4 2026, is exceptionally high compared to typical healthy public companies, which often aim for leverage ratios below 3.0x-4.0x. For example, consumer health companies like Johnson & Johnson or Procter & Gamble typically maintain much lower leverage ratios (e.g., J&J often below 2.0x net debt/EBITDA). This indicates Synergy CHC Corp. is operating with significantly higher financial risk.
• The minimum Fixed Charge Coverage Ratio of 1.20:1.00 is also on the lower end of what is considered healthy, as many companies in stable industries target 2.0x or higher to comfortably cover their fixed obligations.

Corporate Governance

Legal Proceedings

• The Delayed Draw Term Loan proceeds will be used to repay in full the outstanding obligations under the Atrium Settlement Agreement.
• The Company is required to repay in full the outstanding obligations under the Vitabest Settlement Agreement on or prior to July 30, 2025.

Related Party Transactions

• Issuance of a Common Stock Purchase Warrant to Acme Credit Partners Fund I, LP, a lender under the Credit Agreement.
• References to Sanders Notes (Senior Subordinated Debentures and a promissory note to Don A. Sanders) as Subordinated Indebtedness, with specific conditions for interest and principal payments, and subject to Sanders Subordination Agreements.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the 3,000,000 share warrant. The need for stockholder approval for further warrant exercise (above 19.9%) gives shareholders a voice but also highlights the dilutive nature. Increased borrowing costs if equity raise fails could negatively impact profitability and thus shareholder value.
• Lenders (Acme Credit Partners Fund I, LP): Gained a warrant for 3,000,000 shares at a nominal price, providing significant upside potential if the company recovers, and enhanced security in case of default. The amendment also provides stricter financial covenants and mandatory prepayments from equity raises, improving their position.
• Company (Synergy CHC Corp.): Gains short-term cash flow relief through PIK interest and adjusted loan terms, but faces increased financial pressure to meet new covenants and raise substantial equity to avoid higher interest rates.

Next Steps

• Company to seek stockholder approval for warrant issuances exceeding 19.9% beneficial ownership at the next annual meeting, no later than June 30, 2026.
• Company to raise at least $10,000,000 in Net Cash Proceeds from Equity Issuances by September 30, 2026.
• Company to make scheduled principal payments on the Term Loan starting July 1, 2026.
• Company to make $4,000,000 in principal reduction payments to regain Term SOFR election option.
• Company to repay Vitabest Settlement Agreement obligations in full by July 30, 2025.

Key Dates

Recommendation

The terms of this amended credit agreement and warrant issuance strongly suggest Synergy CHC Corp. is in a precarious financial position. The need for PIK interest, extremely high initial leverage ratios (20.00:1.00), and the mandatory equity raise with a penalty for non-compliance indicate significant distress. The issuance of 3,000,000 warrants at a nominal price to a lender, exercisable upon default, represents substantial potential dilution for existing shareholders and a transfer of value to the lender in a downside scenario. While the amendment provides temporary relief, the underlying financial health appears weak, and the path to sustainable recovery is fraught with high execution risk, making the stock a strong sell for investors.

Keywords

Synergy CHC Corp., SNYR, Term Loan, Credit Agreement, Warrant, Equity Issuance, Financial Covenants, EBITDA, Leverage Ratio, Dilution, Corporate Finance, SEC Filing, 8-K, Debt Restructuring, Shareholder Approval